Siga of the USA starts trading on Frankfurt Stock Exchange

27 August 2001

Siga Technologies, a US biopharmaceutical company that focuses onantibiotics and vaccines, has begun trading on the Frankfurt Stock Exchange in Germany. The company's chairman, Donald Drapkin, said the new listing "is a notable achievement which will assist us in the fulfillment of our strategic positioning in the global financial marketplace," and claimed that it will enhance Siga's international exposure.

Chief executive Philip Sussman said that the company is "officially kicking off our listing with a multi-city road show to formally introduce Siga to the investment community on the continent."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight